Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Abstract

Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.).

Keywords

OxaliplatinMedicineRegimenColorectal cancerStage (stratigraphy)AdjuvantOncologyDuration (music)Internal medicineAdjuvant chemotherapyAdjuvant therapyChemotherapyCancer

Affiliated Institutions

Related Publications

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Philip Bonomi , KyungMann Kim , Diane L. Fairclough +5 more

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...

2000 Journal of Clinical Oncology 593 citations

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy

Philip D. Dunne , Darragh G. McArt , Paul G. O’Reilly +9 more

Abstract A recent phase II study of patients with metastatic colorectal carcinoma showed that mismatch repair gene status was predictive of clinical response to PD-1–targeting i...

2016 Cancer Immunology Research 40 citations

Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.

John R. Penrod , Beata Korytowsky , Allison Petrilla +8 more

6582 Background: Prior real-world (RW) studies of advanced non-small cell lung cancer (adv NSCLC) have described overall survival (OS) from diagnosis (Dx) for all patients (pts)...

2014 Journal of Clinical Oncology 17 citations

The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage

Wilma E. Mesker , Jan M. C. Junggeburt , Károly Szuhai +4 more

Background : Tumor staging insufficiently discriminates between colon cancer patients with poor and better prognosis. We have evaluated, for the primary tumor, if the carcinoma‐...

2007 Analytical Cellular Pathology 347 citations

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer , Esmée A. Dijkstra , Boudewijn van Etten +97 more

Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And P...

2020 The Lancet Oncology 1432 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 13
Pages: 1177-1188
Citations: 1045
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1045

OpenAlex

Cite This

APA Style

                            
                                
                                    Axel Grothey, 
                                
                                    Alberto Sobrero, 
                                
                                    Anthony F. Shields
                                
                                et al.
                            
                            (2018). 
                            Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
                            New England Journal of Medicine
                            , 378
                            (13)
                            , 1177-1188.
                            https://doi.org/10.1056/nejmoa1713709
                        

Identifiers

DOI: 10.1056/nejmoa1713709